TRACE-AI Yale
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a condition where abnormal proteins build up in the heart, making it harder for the heart to pump blood effectively. This condition is often underdiagnosed because many patients don't show symptoms until the disease has progressed. Early detection is crucial as new treatments can significantly improve patient outcomes.
The CarDS lab has developed AI-based tools that use existing data, like ECGs and echo videos, to identify people with ATTR-CM. Currently, these AI tools are being tested in the TRACE-AI Yale study to see how well they work in everyday medical practice.
About the study
TRACE-AI Yale is a prospective study funded by BridgeBio. The goal is to see how well artificial intelligence (AI) can screen for ATTR-CM in heart failure patients. These AI-based tests will be compared to the current gold standard diagnostic test, the PYP scan, to see if they can accurately identify ATTR-CM.
By participating in this study, you can help us improve early detection methods for ATTR-CM, potentially leading to better treatment and outcomes for many patients.
-
Eligible participants will be identified by the study team:
To be eligible participants need to be:
18 years or older.
Have an ECG and an Echo test in the Yale New Haven Health System.
Have a heart failure diagnosis
Have a negative pregnancy test (if applicable)
-
The study can be completed in a single visit and take about 1.5 hours. The visit includes brief questionnaires and a PYP Scan.
Participants agree to share their parts of their medical records with researchers.
-
Participants will be compensated $50 for completing this study.
